(Q38403090)

2 September 2017

title

Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin (English)

1 reference

2 September 2017

0 references

1 reference

19

Maier W

1 reference

2 September 2017

Joachim Klosterkötter

21

object named as

Klosterkötter J

1 reference

2 September 2017

Ehrenreich H

1

1 reference

2 September 2017

Hinze-Selch D

2

1 reference

2 September 2017

Stawicki S

3

1 reference

2 September 2017

Aust C

4

1 reference

2 September 2017

Knolle-Veentjer S

5

1 reference

2 September 2017

Wilms S

6

1 reference

2 September 2017

Heinz G

7

1 reference

2 September 2017

Erdag S

8

1 reference

2 September 2017

Jahn H

9

1 reference

2 September 2017

Degner D

10

1 reference

2 September 2017

Ritzen M

11

1 reference

2 September 2017

Mohr A

12

1 reference

2 September 2017

Wagner M

13

1 reference

2 September 2017

Schneider U

14

1 reference

2 September 2017

Bohn M

15

1 reference

2 September 2017

Huber M

16

1 reference

2 September 2017

Czernik A

17

1 reference

2 September 2017

Pollmächer T

18

1 reference

2 September 2017

Sirén AL

20

1 reference

2 September 2017

Falkai P

22

1 reference

2 September 2017

Rüther E

23

1 reference

2 September 2017

Aldenhoff JB

24

1 reference

2 September 2017

Krampe H

25

1 reference

2 September 2017

language of work or name

English

0 references

publication date

10 October 2006

1 reference

2 September 2017

1 reference

2 September 2017

volume

12

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

206-220

1 reference

Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Epidemiology of schizophrenia. A thriving discipline at the turn of the century

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Neurocognitive, social, and emotional dysfunction in deficit syndrome schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Cross-national diagnosis of schizophrenia in twins. The heritability and specificity of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Schizophrenia: from dopamine to glutamate and back

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Another view of therapy for cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Brain volume changes in first-episode schizophrenia: a 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Longitudinal study of brain morphology in first episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Theories of schizophrenia: a genetic-inflammatory-vascular synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Schizophrenia as a disorder of neurodevelopment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Neuroprotection--what does it mean?--What means do we have?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Emerging biological roles for erythropoietin in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Erythropoietin: novel approaches to neuroprotection in human brain disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Medicine. A boost for translational neuroscience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

In vivo evidence that erythropoietin protects neurons from ischemic damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Erythropoietin improves synaptic transmission during and following ischemia in rat hippocampal slice cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Cognitive functioning in schizophrenia and bipolar disorder: comparison of performance on the Repeatable Battery for the Assessment of Neuropsychological Status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Identification of separable cognitive factors in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Anemia of inflammation: the cytokine-hepcidin link

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Hepcidin in iron metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Antipsychotic drug effects on brain morphology in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Molecular psychology: roles for the ERK MAP kinase cascade in memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Effects of erythropoietin on neuronal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

The S100 protein family: history, function, and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Glial protein S100B modulates long-term neuronal synaptic plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Derivatives of erythropoietin that are tissue protective but not erythropoietic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Tainted glory--doping and athletic performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Schizophrenia: the fundamental questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Erythropoietin abuse in athletes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

Emerging principles of altered neural circuitry in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

7 January 2021

Erythropoietin: a candidate compound for neuroprotection in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

7 January 2021

Erythropoietin therapy for acute stroke is both safe and beneficial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

7 January 2021

Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001907

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4001907

1 reference

Dimensions Publication ID

2 September 2017

1008256404

0 references

1 reference